Navigation Links
Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases

Top Scientists Meet for Global Conference On Stem Cell Therapy for Cardiovascular Diseases

Scientific Meeting on Ground-breaking Advances, Pioneering Innovations In Cell-Based Therapeutic Approaches to Cardiovascular Diseases

WHAT: The Cardiovascular Research Foundation (CRF) brings experts to New York City from around the world for the Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases. Dedicated to new advances in this emerging field, the three-day session will feature an in-depth review of cell-based therapies for myocardial repair and regeneration, angiogenesis and cutting-edge research findings. Highlights include:

  • Clinical Focus: Full-day programs for the discussion of heart attacks (ST elevation myocardial infarction, or STEMI) and congestive heart failure (CHF). Each will cover strategies using cell-based therapies to address the chronic ventricular dysfunction underlying these conditions.

  • Special Sessions on:
    • Cardiac Tissue Engineering, including exciting work in constructing blood vessels and cell sheets of myocardial tissue
    • Angiogenesis, including the use of stem cells derived from bone marrow, adipose, and other sources to synthesize functioning myocardium in patients with heart and peripheral vascular disease

  • Late Breaking Clinical Trials:

    • Results from two major trials (TOPCARE, REPAIR-AMI) of bone-marrow- or blood-derived progenitor cells for acute myocardial infarction will be reviewed by Dr. Andreas M. Zeiher
    • Intravenous allogeneic mesenchymal stem cells for acute myocardial infarction will be presented by Dr. Joshua M. Hare
    • MAGIC 5: combined approach using granulocyte colony stimulating factor (G-CSF), erythropoietin mobilization, and intracoronary cell infusion in patients with heart attack, presented in detail here by Dr. Hyo-Soo Kim
    • Bone marrow-derived stem cells for patients with chronic limb ischemia, presented by Dr. Brian Annex
    • Transplantation of bone marrow stem cells for persistent, refractory angina, presented and discussed by Drs. Douglas Losordo and Jorge Tuma
    • CausMic: A randomized, controlled study of myoblasts in patients with heart failure, first reported at AHA 2007, presented in detail here by Dr. Nabil Dib
    • Stem cells in patients with heart failure on left ventricular assist devices, presented by Dr. Eric A. Rose

  • Next-Generation Heart Muscle Cells: Advances in skeletal, myocardial, embryonic, and bone marrow derived techniques

  • A Preview of First-in-Human Studies Planned for the Coming Year
    • MARVEL: the largest randomized placebo-controlled study of skeletal myoblasts in patients with heart failure, presented by Dr. Warren Sherman
    • PRIMO-AMI; a novel bone-marrow derived cell and injection technique in patients with heart attack, presented by Dr. Marc Penn.

WHO: Hundreds of the worlds leading cell therapy experts will meet to discuss the latest advances in this area.

Warren Sherman, M.D., Conference Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patients own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.

WHEN: January 16 18, 2008

WHERE: Columbia University, Alfred Lerner Hall, 2920 Broadway (at 115th St.), New York, NY

For media inquiries and registration, please contact Irma Damhuis (212-851-9187; , Claire Laporte (212-851-9311; or Alex Lyda (212-305-0820;

The conference program can be found at


Contact: Claire Laporte
Cardiovascular Research Foundation

Related biology news :

1. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
2. CIC Again Named to Software Magazines Annual Prestigious Software 500 List
3. Colony collapse disorder symposium added to ESA Annual Meeting
4. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
5. Canadian Society of Exercise Physiology Annual Scientific Conference
6. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
7. ESMO International Symposium on Immunology
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
Post Your Comments:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: